Stereotactic radiotherapy for treatment of cavernous sinus meningiomas

To assess the safety and efficacy of stereotactic radiotherapy (SRT) using a linear accelerator equipped with a micromultileaf collimator for cavernous sinus meningiomas. Forty-five patients with benign cavernous sinus meningiomas were treated with SRT between November 1997 and April 2002. Sixteen p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2004-05, Vol.59 (1), p.101-111
Hauptverfasser: Selch, Michael T, Ahn, Eugene, Laskari, Ashkan, Lee, Steve P, Agazaryan, Nhzde, Solberg, Timothy D, Cabatan-Awang, Cynthia, Frighetto, Leonardo, Desalles, Antonio A.F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 111
container_issue 1
container_start_page 101
container_title International journal of radiation oncology, biology, physics
container_volume 59
creator Selch, Michael T
Ahn, Eugene
Laskari, Ashkan
Lee, Steve P
Agazaryan, Nhzde
Solberg, Timothy D
Cabatan-Awang, Cynthia
Frighetto, Leonardo
Desalles, Antonio A.F
description To assess the safety and efficacy of stereotactic radiotherapy (SRT) using a linear accelerator equipped with a micromultileaf collimator for cavernous sinus meningiomas. Forty-five patients with benign cavernous sinus meningiomas were treated with SRT between November 1997 and April 2002. Sixteen patients received definitive treatment on the basis of imaging characteristics of the cavernous sinus tumor. Twenty-nine patients received SRT either as immediate adjuvant treatment after incomplete resection or at documented recurrence. Treatment planning in all patients included CT–MRI image fusion and beam shaping using a micromultileaf collimator. The primary tumor volume varied from 1.41 to 65.66 cm 3 (median, 14.5 cm 3). The tumor diameter varied from 1.4 to 7.4 cm (median, 3.8 cm). Tumor compressed the optic chiasm or optic nerve in 30 patients. All tumors were treated with a single isocenter plus a margin of normal parenchyma varying from 1 to 5 mm (median, 2.5 mm). The prescribed dose varied from 4250 to 5400 cGy (median, 5040 cGy). The prescription isodose varied from 87% to 95% (median, 90%). The maximal tumor dose varied from 5000 to 6000 cGy (median, 5600 cGy). The follow-up varied from 12 to 53 months (median, 36 months). The actuarial 3-year overall and progression-free survival rate was 100% and 97.4%, respectively. One patient (2%) developed local relapsed at 18 months. A partial imaging response occurred in 18% of patients, and the tumor was stable in the remaining 80%. Preexisting neurologic complaints improved in 20% of patients and were stable in the remainder. No patient, tumor, or treatment factors were found to be predictive of imaging or clinical response. Transient acute morbidities included headache responsive to nonnarcotic analgesics in 4 patients, fatigue in 3 patients, and retroorbital pain in 1 patient. No treatment-induced peritumoral edema, cranial neuropathy, endocrine dysfunction, cognitive decline, or second malignancy occurred. One patient had an ipsilateral cerebrovascular accident 6 months after SRT. Stereotactic radiotherapy is both safe and effective for patients with cavernous sinus meningiomas. Field shaping using a micromultileaf collimator allows conformal and homogeneous radiation of cavernous sinus meningiomas that may not be amenable to single-fraction stereotactic radiosurgery because of tumor size or location. Additional clinical experience is necessary to determine the position of SRT among the available innovat
doi_str_mv 10.1016/j.ijrobp.2003.09.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71852473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301603019230</els_id><sourcerecordid>71852473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-f0b87e19c5763ad8319b01ad433c05dc0466d154849603eedc2887c7621335543</originalsourceid><addsrcrecordid>eNqFkc9rVDEQx4NY7Fr9D0TeRW_vdfLy-1KQ0qpQ6KEK3kI2madZ9r1sk2yh_70pu9Ce9DJfGD4zTD4h5AOFgQKV55shbnJa74YRgA1ghhavyIpqZXomxK_XZAVMQs8afErelrIBAEoVf0NOqQDDDIgVub6rmDFV52v0XXYhpvoHs9s9dlPKXc3o6oxL7dLUefeAeUn70pW4tNr6cfkd0-zKO3IyuW3B98c8Iz-vr35cfutvbr9-v_xy03uuVe0nWGuF1HihJHNBM2rWQF3gjHkQwQOXMlDBNTcSGGLwo9bKKzlS1t7E2Rn5fNi7y-l-j6XaORaP261bsB1mFdVi5Ir9FxxBcwnCNJAfQJ9TKRknu8txdvnRUrBPou3GHkTbJ9EWjG3Rxj4e9-_XM4bnoaPZBnw6Aq54t52yW3wsLzjVPkOqxl0cOGzaHiJmW3zExWOIGX21IcV_X_IX1h-dPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20846059</pqid></control><display><type>article</type><title>Stereotactic radiotherapy for treatment of cavernous sinus meningiomas</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Selch, Michael T ; Ahn, Eugene ; Laskari, Ashkan ; Lee, Steve P ; Agazaryan, Nhzde ; Solberg, Timothy D ; Cabatan-Awang, Cynthia ; Frighetto, Leonardo ; Desalles, Antonio A.F</creator><creatorcontrib>Selch, Michael T ; Ahn, Eugene ; Laskari, Ashkan ; Lee, Steve P ; Agazaryan, Nhzde ; Solberg, Timothy D ; Cabatan-Awang, Cynthia ; Frighetto, Leonardo ; Desalles, Antonio A.F</creatorcontrib><description>To assess the safety and efficacy of stereotactic radiotherapy (SRT) using a linear accelerator equipped with a micromultileaf collimator for cavernous sinus meningiomas. Forty-five patients with benign cavernous sinus meningiomas were treated with SRT between November 1997 and April 2002. Sixteen patients received definitive treatment on the basis of imaging characteristics of the cavernous sinus tumor. Twenty-nine patients received SRT either as immediate adjuvant treatment after incomplete resection or at documented recurrence. Treatment planning in all patients included CT–MRI image fusion and beam shaping using a micromultileaf collimator. The primary tumor volume varied from 1.41 to 65.66 cm 3 (median, 14.5 cm 3). The tumor diameter varied from 1.4 to 7.4 cm (median, 3.8 cm). Tumor compressed the optic chiasm or optic nerve in 30 patients. All tumors were treated with a single isocenter plus a margin of normal parenchyma varying from 1 to 5 mm (median, 2.5 mm). The prescribed dose varied from 4250 to 5400 cGy (median, 5040 cGy). The prescription isodose varied from 87% to 95% (median, 90%). The maximal tumor dose varied from 5000 to 6000 cGy (median, 5600 cGy). The follow-up varied from 12 to 53 months (median, 36 months). The actuarial 3-year overall and progression-free survival rate was 100% and 97.4%, respectively. One patient (2%) developed local relapsed at 18 months. A partial imaging response occurred in 18% of patients, and the tumor was stable in the remaining 80%. Preexisting neurologic complaints improved in 20% of patients and were stable in the remainder. No patient, tumor, or treatment factors were found to be predictive of imaging or clinical response. Transient acute morbidities included headache responsive to nonnarcotic analgesics in 4 patients, fatigue in 3 patients, and retroorbital pain in 1 patient. No treatment-induced peritumoral edema, cranial neuropathy, endocrine dysfunction, cognitive decline, or second malignancy occurred. One patient had an ipsilateral cerebrovascular accident 6 months after SRT. Stereotactic radiotherapy is both safe and effective for patients with cavernous sinus meningiomas. Field shaping using a micromultileaf collimator allows conformal and homogeneous radiation of cavernous sinus meningiomas that may not be amenable to single-fraction stereotactic radiosurgery because of tumor size or location. Additional clinical experience is necessary to determine the position of SRT among the available innovative fractionated RT options for challenging skull base meningiomas.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2003.09.003</identifier><identifier>PMID: 15093905</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cavernous Sinus ; Cavernous sinus meningioma ; Female ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Meningeal Neoplasms - surgery ; Meningioma - surgery ; Micromultileaf collimator ; Middle Aged ; Radiosurgery - instrumentation ; Radiotherapy Dosage ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Stereotactic radiotherapy ; Survival Rate ; Technology. Biomaterials. Equipments. Material. Instrumentation</subject><ispartof>International journal of radiation oncology, biology, physics, 2004-05, Vol.59 (1), p.101-111</ispartof><rights>2004 Elsevier Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-f0b87e19c5763ad8319b01ad433c05dc0466d154849603eedc2887c7621335543</citedby><cites>FETCH-LOGICAL-c487t-f0b87e19c5763ad8319b01ad433c05dc0466d154849603eedc2887c7621335543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2003.09.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3536,23910,23911,25119,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15701167$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15093905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Selch, Michael T</creatorcontrib><creatorcontrib>Ahn, Eugene</creatorcontrib><creatorcontrib>Laskari, Ashkan</creatorcontrib><creatorcontrib>Lee, Steve P</creatorcontrib><creatorcontrib>Agazaryan, Nhzde</creatorcontrib><creatorcontrib>Solberg, Timothy D</creatorcontrib><creatorcontrib>Cabatan-Awang, Cynthia</creatorcontrib><creatorcontrib>Frighetto, Leonardo</creatorcontrib><creatorcontrib>Desalles, Antonio A.F</creatorcontrib><title>Stereotactic radiotherapy for treatment of cavernous sinus meningiomas</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>To assess the safety and efficacy of stereotactic radiotherapy (SRT) using a linear accelerator equipped with a micromultileaf collimator for cavernous sinus meningiomas. Forty-five patients with benign cavernous sinus meningiomas were treated with SRT between November 1997 and April 2002. Sixteen patients received definitive treatment on the basis of imaging characteristics of the cavernous sinus tumor. Twenty-nine patients received SRT either as immediate adjuvant treatment after incomplete resection or at documented recurrence. Treatment planning in all patients included CT–MRI image fusion and beam shaping using a micromultileaf collimator. The primary tumor volume varied from 1.41 to 65.66 cm 3 (median, 14.5 cm 3). The tumor diameter varied from 1.4 to 7.4 cm (median, 3.8 cm). Tumor compressed the optic chiasm or optic nerve in 30 patients. All tumors were treated with a single isocenter plus a margin of normal parenchyma varying from 1 to 5 mm (median, 2.5 mm). The prescribed dose varied from 4250 to 5400 cGy (median, 5040 cGy). The prescription isodose varied from 87% to 95% (median, 90%). The maximal tumor dose varied from 5000 to 6000 cGy (median, 5600 cGy). The follow-up varied from 12 to 53 months (median, 36 months). The actuarial 3-year overall and progression-free survival rate was 100% and 97.4%, respectively. One patient (2%) developed local relapsed at 18 months. A partial imaging response occurred in 18% of patients, and the tumor was stable in the remaining 80%. Preexisting neurologic complaints improved in 20% of patients and were stable in the remainder. No patient, tumor, or treatment factors were found to be predictive of imaging or clinical response. Transient acute morbidities included headache responsive to nonnarcotic analgesics in 4 patients, fatigue in 3 patients, and retroorbital pain in 1 patient. No treatment-induced peritumoral edema, cranial neuropathy, endocrine dysfunction, cognitive decline, or second malignancy occurred. One patient had an ipsilateral cerebrovascular accident 6 months after SRT. Stereotactic radiotherapy is both safe and effective for patients with cavernous sinus meningiomas. Field shaping using a micromultileaf collimator allows conformal and homogeneous radiation of cavernous sinus meningiomas that may not be amenable to single-fraction stereotactic radiosurgery because of tumor size or location. Additional clinical experience is necessary to determine the position of SRT among the available innovative fractionated RT options for challenging skull base meningiomas.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cavernous Sinus</subject><subject>Cavernous sinus meningioma</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Meningeal Neoplasms - surgery</subject><subject>Meningioma - surgery</subject><subject>Micromultileaf collimator</subject><subject>Middle Aged</subject><subject>Radiosurgery - instrumentation</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Stereotactic radiotherapy</subject><subject>Survival Rate</subject><subject>Technology. Biomaterials. Equipments. Material. Instrumentation</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9rVDEQx4NY7Fr9D0TeRW_vdfLy-1KQ0qpQ6KEK3kI2madZ9r1sk2yh_70pu9Ce9DJfGD4zTD4h5AOFgQKV55shbnJa74YRgA1ghhavyIpqZXomxK_XZAVMQs8afErelrIBAEoVf0NOqQDDDIgVub6rmDFV52v0XXYhpvoHs9s9dlPKXc3o6oxL7dLUefeAeUn70pW4tNr6cfkd0-zKO3IyuW3B98c8Iz-vr35cfutvbr9-v_xy03uuVe0nWGuF1HihJHNBM2rWQF3gjHkQwQOXMlDBNTcSGGLwo9bKKzlS1t7E2Rn5fNi7y-l-j6XaORaP261bsB1mFdVi5Ir9FxxBcwnCNJAfQJ9TKRknu8txdvnRUrBPou3GHkTbJ9EWjG3Rxj4e9-_XM4bnoaPZBnw6Aq54t52yW3wsLzjVPkOqxl0cOGzaHiJmW3zExWOIGX21IcV_X_IX1h-dPg</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Selch, Michael T</creator><creator>Ahn, Eugene</creator><creator>Laskari, Ashkan</creator><creator>Lee, Steve P</creator><creator>Agazaryan, Nhzde</creator><creator>Solberg, Timothy D</creator><creator>Cabatan-Awang, Cynthia</creator><creator>Frighetto, Leonardo</creator><creator>Desalles, Antonio A.F</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Stereotactic radiotherapy for treatment of cavernous sinus meningiomas</title><author>Selch, Michael T ; Ahn, Eugene ; Laskari, Ashkan ; Lee, Steve P ; Agazaryan, Nhzde ; Solberg, Timothy D ; Cabatan-Awang, Cynthia ; Frighetto, Leonardo ; Desalles, Antonio A.F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-f0b87e19c5763ad8319b01ad433c05dc0466d154849603eedc2887c7621335543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cavernous Sinus</topic><topic>Cavernous sinus meningioma</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Meningeal Neoplasms - surgery</topic><topic>Meningioma - surgery</topic><topic>Micromultileaf collimator</topic><topic>Middle Aged</topic><topic>Radiosurgery - instrumentation</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Stereotactic radiotherapy</topic><topic>Survival Rate</topic><topic>Technology. Biomaterials. Equipments. Material. Instrumentation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Selch, Michael T</creatorcontrib><creatorcontrib>Ahn, Eugene</creatorcontrib><creatorcontrib>Laskari, Ashkan</creatorcontrib><creatorcontrib>Lee, Steve P</creatorcontrib><creatorcontrib>Agazaryan, Nhzde</creatorcontrib><creatorcontrib>Solberg, Timothy D</creatorcontrib><creatorcontrib>Cabatan-Awang, Cynthia</creatorcontrib><creatorcontrib>Frighetto, Leonardo</creatorcontrib><creatorcontrib>Desalles, Antonio A.F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Selch, Michael T</au><au>Ahn, Eugene</au><au>Laskari, Ashkan</au><au>Lee, Steve P</au><au>Agazaryan, Nhzde</au><au>Solberg, Timothy D</au><au>Cabatan-Awang, Cynthia</au><au>Frighetto, Leonardo</au><au>Desalles, Antonio A.F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic radiotherapy for treatment of cavernous sinus meningiomas</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>59</volume><issue>1</issue><spage>101</spage><epage>111</epage><pages>101-111</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>To assess the safety and efficacy of stereotactic radiotherapy (SRT) using a linear accelerator equipped with a micromultileaf collimator for cavernous sinus meningiomas. Forty-five patients with benign cavernous sinus meningiomas were treated with SRT between November 1997 and April 2002. Sixteen patients received definitive treatment on the basis of imaging characteristics of the cavernous sinus tumor. Twenty-nine patients received SRT either as immediate adjuvant treatment after incomplete resection or at documented recurrence. Treatment planning in all patients included CT–MRI image fusion and beam shaping using a micromultileaf collimator. The primary tumor volume varied from 1.41 to 65.66 cm 3 (median, 14.5 cm 3). The tumor diameter varied from 1.4 to 7.4 cm (median, 3.8 cm). Tumor compressed the optic chiasm or optic nerve in 30 patients. All tumors were treated with a single isocenter plus a margin of normal parenchyma varying from 1 to 5 mm (median, 2.5 mm). The prescribed dose varied from 4250 to 5400 cGy (median, 5040 cGy). The prescription isodose varied from 87% to 95% (median, 90%). The maximal tumor dose varied from 5000 to 6000 cGy (median, 5600 cGy). The follow-up varied from 12 to 53 months (median, 36 months). The actuarial 3-year overall and progression-free survival rate was 100% and 97.4%, respectively. One patient (2%) developed local relapsed at 18 months. A partial imaging response occurred in 18% of patients, and the tumor was stable in the remaining 80%. Preexisting neurologic complaints improved in 20% of patients and were stable in the remainder. No patient, tumor, or treatment factors were found to be predictive of imaging or clinical response. Transient acute morbidities included headache responsive to nonnarcotic analgesics in 4 patients, fatigue in 3 patients, and retroorbital pain in 1 patient. No treatment-induced peritumoral edema, cranial neuropathy, endocrine dysfunction, cognitive decline, or second malignancy occurred. One patient had an ipsilateral cerebrovascular accident 6 months after SRT. Stereotactic radiotherapy is both safe and effective for patients with cavernous sinus meningiomas. Field shaping using a micromultileaf collimator allows conformal and homogeneous radiation of cavernous sinus meningiomas that may not be amenable to single-fraction stereotactic radiosurgery because of tumor size or location. Additional clinical experience is necessary to determine the position of SRT among the available innovative fractionated RT options for challenging skull base meningiomas.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15093905</pmid><doi>10.1016/j.ijrobp.2003.09.003</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0360-3016
ispartof International journal of radiation oncology, biology, physics, 2004-05, Vol.59 (1), p.101-111
issn 0360-3016
1879-355X
language eng
recordid cdi_proquest_miscellaneous_71852473
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Cavernous Sinus
Cavernous sinus meningioma
Female
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Male
Medical sciences
Meningeal Neoplasms - surgery
Meningioma - surgery
Micromultileaf collimator
Middle Aged
Radiosurgery - instrumentation
Radiotherapy Dosage
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Stereotactic radiotherapy
Survival Rate
Technology. Biomaterials. Equipments. Material. Instrumentation
title Stereotactic radiotherapy for treatment of cavernous sinus meningiomas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T02%3A15%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20radiotherapy%20for%20treatment%20of%20cavernous%20sinus%20meningiomas&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Selch,%20Michael%20T&rft.date=2004-05-01&rft.volume=59&rft.issue=1&rft.spage=101&rft.epage=111&rft.pages=101-111&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2003.09.003&rft_dat=%3Cproquest_cross%3E71852473%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20846059&rft_id=info:pmid/15093905&rft_els_id=S0360301603019230&rfr_iscdi=true